Biosolids Treatment Sample Clauses

Biosolids Treatment. Process Evaluation and Selection It has been established that the SFPUC, at a minimum wiii upgrade its soiids handling treatment to produce a Class A biosolids product. The feed stream may include solids from wastewater/stormwater, fats, oils, grease (FOG), food waste and any other waste stream amenable to anaerobic digestion with the proper pre-treatment processes. Each waste stream will require additional characterization to determine impact to the overall process. Other treatment processes producing advanced biosolids products may be evaluated if they are found to be sustainable and viable use options for the SFPUC based on a cost/benefit market analyses. Conduct treatment process selection evaluations of the viable technology alternatives that address at a minimum the following: objective of the project, benefit, maturity of technology, disadvantages, operating criteria, ease of maintenance, reliability, instrumentation and controls, associated equipment appurtenances, life cycle cost, capital cost and risk. The goal of the evaluations is to reach a consensus for a recommended treatment process for each key process in the SEP BDFP. Under the SSIP, standard Triple Bottom Line (TBL) criteria are being developed. Using the SSIP TB L criteria as a basis (if appiicable), the Contractor will develop agreed-upon evaluation criteria with the SFPUC prior to commencement of the selection analysis. Extensive workshops will be conducted with SFPUC staff to solicit input and provide information exchange and consensus building. The solids process modeling must be integrated into the model. Any process modei(s) used in the anaiysis shall be transferred to the City foiiowing completion of the Project. The treatment processes to be evaluated as part of this project include, but are not to: • Thermal hydrolysis; • Thickening; • Digestion (separate and/or co-digestion); • Dewatering; • Thermal drying technologies; • Other processes producing Class A biosolids products; • Other processes producing advanced biosolids products; and • Other associated processes for handling of any byproducts or waste streams.
Sample 1
AutoNDA by SimpleDocs
Biosolids Treatment 
Sample 1

Related to Biosolids Treatment

  • Medical Treatment Undersigned understands that the Released Parties do not have medical personnel available at the location of the activities. Undersigned hereby grants the Released Parties permission to administer first aid or to authorize emergency medical treatment, if necessary. Undersigned understands and agrees that any such action by the Released Parties shall be subject to the terms of this agreement and release, including any liability arising from the negligence of the Released Parties when administering first aid or authorizing others to do so. Undersigned understands and agrees that the Released Parties do not assume responsibility for any injury or damage which might arise out of or in connection with such authorized emergency medical treatment.

  • Xxx Treatment We have not promised you any particular tax outcome from buying or holding the Note.

  • Emergency Medical Treatment I grant the Releasees permission to authorize emergency medical treatment as they deem appropriate, and agree that such action by the Releasees shall be subject to the terms of this Agreement. I understand and agree that the Releasees assume no responsibility for any injury or damage that might result from such emergency medical treatment.

  • National Treatment and Most-favoured-nation Treatment (1) Each Contracting Party shall accord to investments of investors of the other Contracting Party, treatment which shall not be less favourable than that accorded either to investments of its own or investments of investors of any third State. (2) In addition, each Contracting Party shall accord to investors of the other Contracting Party, including in respect of returns on their investments, treatment which shall not be less favourable than that accorded to investors of any third State. (3) The provisions of paragraphs (1) and (2) above shall not be construed so as to oblige one Contracting Party to extend to the investors of the other the benefit of any treatment, preference or privilege resulting from: (a) Any existing or future free trade area, customs unions, monetary union or similar international agreement or other forms of regional cooperation to which one of the Contracting Parties is or may become a party, or (b) Any matter pertaining wholly or mainly to taxation.

  • National Treatment In the sectors inscribed in its Schedule, and subject to any conditions and qualifications set out therein, each Party shall accord to services and service suppliers of the other Party treatment no less favourable than that it accords, in like circumstances, to its own services and service suppliers.

  • Substance Abuse Treatment Information Substance abuse treatment information shall be maintained in compliance with 42 C.F.R. Part 2 if the Party or subcontractor(s) are Part 2 covered programs, or if substance abuse treatment information is received from a Part 2 covered program by the Party or subcontractor(s).

  • Sale Treatment The Company has determined that the disposition of the Mortgage Loans pursuant to this Agreement will be afforded sale treatment for accounting and tax purposes;

  • Treatment The Asset Representations Reviewer agrees to hold and treat Confidential Information given to it under this Agreement in confidence and under the terms and conditions of this Section 4.08, and will implement and maintain safeguards to further assure the confidentiality of the Confidential Information. The Confidential Information will not, without the prior consent of the Issuer and the Servicer, be disclosed or used by the Asset Representations Reviewer, or its officers, directors, employees, agents, representatives or affiliates, including legal counsel (collectively, the “Information Recipients”) other than for the purposes of performing Reviews of Review Receivables or performing its obligations under this Agreement. The Asset Representations Reviewer agrees that it will not, and will cause its Affiliates to not (i) purchase or sell securities issued by the Seller or its Affiliates or special purpose entities on the basis of Confidential Information or (ii) use the Confidential Information for the preparation of research reports, newsletters or other publications or similar communications.

  • REIT Treatment The Company will use its reasonable efforts to enable the Company to continue to meet the requirements to qualify for taxation as a REIT under the Code for subsequent tax years that include any portion of the term of this Agreement except as otherwise determined by the Board of Directors of the Company to be in the best interests of stockholders.

  • Musculoskeletal Injury Prevention and Control The hospital in consultation with the Joint Health and Safety Committee (JHSC) shall develop, establish and put into effect, musculoskeletal prevention and control measures, procedures, practices and training for the health and safety of employees.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!